Hoth Therapeutics, Inc.
HOTH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HOTH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HOTH
Hoth Therapeutics, Inc. is a pre-revenue biopharmaceutical company focused on developing novel therapies for unmet medical needs, currently advancing preclinical and clinical-stage product candidates while facing significant operating losses and a going concern risk.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$19.2M
Cash Runway
—
Lead Asset
biolexa (Phase 1)
Next Catalyst
—
Tracking 2 pipeline candidates for Hoth Therapeutics, Inc..
Hoth Therapeutics, Inc. is a pre-revenue biopharmaceutical company focused on developing novel therapies for unmet medical needs, currently advancing preclinical and clinical-stage product candidates while facing significant operating losses and a going concern risk.
- Hoth Therapeutics has an accumulated deficit of approximately $75.6 million as of March 31, 2026 [sec_mda · as of 2026-05-15].
- The company reported a net loss of $2.7 million for the three months ended March 31, 2026 [sec_mda · as of 2026-05-15].
- Cash and cash equivalents were approximately $4.0 million as of March 31, 2026 [sec_mda · as of 2026-05-15].
- The company has not yet commercialized any products and has never generated any revenue from product sales [sec_mda · as of 2025-11-12].
- Hoth Therapeutics' ability to continue as a going concern is dependent on raising additional capital to fund research and development activities [sec_mda · as of 2026-05-15].
What works
- The company has a pipeline of preclinical and clinical-stage product candidates targeting various therapeutic areas, indicating potential for future value if development succeeds [sec_mda · as of 2025-11-12].
- Hoth Therapeutics has access to potential milestone payments of up to approximately $36 million from existing agreements, which could provide non-dilutive funding upon achievement of development or commercialization events [sec_mda · as of 2025-08-12].
What to weigh
- The company has incurred substantial operating losses since inception and expects to continue incurring significant losses for the foreseeable future, with no product revenue to date [sec_mda · as of 2025-11-12].
- Hoth Therapeutics faces a going concern risk, as its ability to fund operations depends on raising additional capital through equity or debt sales [sec_mda · as of 2026-05-15].
- The company has a limited cash runway, with cash and equivalents of $4.0 million as of March 31, 2026, which may not be sufficient to fund all planned activities without further financing [sec_mda · as of 2026-05-15].
From the filings
Quoted directly from source documents.
The company has a substantial accumulated deficit and ongoing losses.
“As of March 31, 2026, we had approximately $4,047,000 in cash and cash equivalents, working capital of approximately $3,425,000 and an accumulated deficit of approximately $75,572,000.”
SEC MD&A · May 15, 2026
The company has never generated product revenue.
“We have not yet commercialized any products and have never generated any revenue from product sales.”
SEC MD&A · November 12, 2025
The company's viability depends on raising additional capital.
“a going concern is dependent on our ability to raise additional capital to fund our research and development ("R&D") activities and meet our obligations on a timely basis.”
SEC MD&A · May 15, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Company's ability to continue operations depends on raising additional capital; no assurance of funding [sec_mda · as of 2026-05-15].
- No product revenue — Hoth has never generated revenue from product sales and may never achieve profitability [sec_mda · as of 2025-11-12].
- Significant accumulated deficit — Accumulated deficit of $75.6 million as of March 31, 2026, with ongoing net losses [sec_mda · as of 2026-05-15].
- Dependence on milestone payments — Potential milestone payments of up to $36 million are contingent on development/commercialization events [sec_mda · as of 2025-08-12].
What to watch
- Ability to raise additional capital through equity or debt offerings to fund operations and extend cash runway [sec_mda · as of 2026-05-15].
- Progress of preclinical and clinical development of product candidates, including any data readouts or regulatory milestones [sec_mda · as of 2025-11-12].
- Achievement of development or commercialization events that trigger milestone payments from existing agreements [sec_mda · as of 2025-08-12].
Sources: SEC MD&A · Generated August 10, 2026 · How we verify sources →
Run Hoth Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Hoth Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Hoth Therapeutics, Inc.?
Hoth Therapeutics, Inc. is a pre-revenue biopharmaceutical company focused on developing novel therapies for unmet medical needs, currently advancing preclinical and clinical-stage product candidates while facing significant operating losses and a going concern risk.
What is Hoth Therapeutics, Inc.'s lead drug candidate?
Hoth Therapeutics, Inc.'s most advanced tracked candidate is biolexa (Phase 1) for atopic dermatitis (eczema).
Who is the CEO of Hoth Therapeutics, Inc.?
Mr. Robb Knie is the chief executive officer of Hoth Therapeutics, Inc. (HOTH).
Where is Hoth Therapeutics, Inc. headquartered?
Hoth Therapeutics, Inc. (HOTH) is headquartered in Hoboken, NJ, United States.
What therapeutic areas does Hoth Therapeutics, Inc. focus on?
Hoth Therapeutics, Inc. develops therapies across Oncology, Neurology, Immunology, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.